Trimethoprim-Sulfamethoxazole Dosage for MRSA Skin Infections

Oral Treatment Options for MRSA Skin Infections

The Infectious Diseases Society of America recommends trimethoprim-sulfamethoxazole (TMP-SMX) as a bactericidal agent with established efficacy against MRSA skin and soft tissue infections (SSTIs) in adults and children, with a standard adult dosing of 1-2 double-strength tablets (160mg/800mg) twice daily for 5-10 days 1, 2, 3, 4, 5
For pediatric patients, the recommended dosing is 8-12 mg/kg/day (based on the trimethoprim component) in either 4 divided doses IV or 2 divided doses orally, with a duration of therapy of 5-10 days based on clinical response 3, 4, 1, 6

The American College of Emergency Physicians and the Infectious Diseases Society of America recommend TMP-SMX as first-line empiric therapy for community-acquired MRSA (CA-MRSA) skin infections, including purulent cellulitis, with empirical therapy pending culture results 1, 7, 8

Alternative oral options for MRSA skin infections include clindamycin 300-450mg three times daily, doxycycline or minocycline 100mg twice daily, and linezolid 600mg twice daily, as recommended by the Infectious Diseases Society of America 1, 4, 7

The Infectious Diseases Society of America recommends considering intravenous therapy for complicated SSTIs, including deeper infections, surgical/traumatic wound infections, and major abscesses, with options such as vancomycin, linezolid, daptomycin, telavancin, or clindamycin, and a duration of 7-14 days 1, 7, 8

The Infectious Diseases Society of America recommends incision and drainage as the primary treatment for purulent skin abscesses, with antibiotics as adjunctive therapy, and considering antibiotic therapy for abscesses with severe or extensive disease, rapid progression with cellulitis, systemic illness, immunosuppression, extremes of age, or difficult-to-drain locations 1, 8, 9